Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study

Fulvia Mancini, Arianna Cianciosi, Nicola Persico, Fabio Facchinetti, Paolo Busacchi, Cesare Battaglia

Research output: Contribution to journalArticle

Abstract

Objective: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). Study Design: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. Results: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. Conclusion: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.

Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume202
Issue number2
DOIs
Publication statusPublished - Feb 2010

Keywords

  • Drospirenone
  • endothelin-1
  • flow-mediated dilatation
  • leptin
  • polycystic ovary syndrome

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study'. Together they form a unique fingerprint.

  • Cite this